Eindhoven, Netherlands

Sonia Chothani

This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignee: Koninklijke Philips Corporation N.v.. Active years: 2020-2022.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2022

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Sonia Chothani

Introduction

Sonia Chothani is a prominent inventor based in Eindhoven, Netherlands. She has made significant contributions to the field of antimicrobial resistance and infection management. With a total of 2 patents, her work focuses on utilizing advanced technologies to address critical health challenges.

Latest Patents

Sonia's latest patents include "Methods of displaying the antimicrobial sensitivity of biological isolates" and "Methods and systems for monitoring and determining antimicrobial resistance and antimicrobial treatment using genomic subtype information." These innovations leverage molecular epidemiology and next-generation sequencing technologies (NGS) to monitor multi-drug resistant pathogens. They provide early insights into emergent microbial threats, which is crucial for effective infection management and control.

Career Highlights

Sonia Chothani is associated with Koninklijke Philips Corporation N.V., where she applies her expertise in developing solutions for antimicrobial resistance. Her work is instrumental in enhancing healthcare outcomes through innovative technologies.

Collaborations

Sonia collaborates with talented professionals such as Sitharthan Kamalakaran and Pramod Mayigowda, contributing to a dynamic research environment focused on tackling pressing health issues.

Conclusion

Sonia Chothani's contributions to the field of antimicrobial resistance through her patents and collaborations highlight her commitment to advancing healthcare technology. Her work is vital in the ongoing battle against multi-drug resistant pathogens.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…